Biomarker Hunt Finds Potential With ctDNA in Melanoma
David Polsky, MD, PhD, discusses the development and clinical utility of biomarkers in melanoma.
Related Articles
FDA Grants Orphan Drug Designation to IMM-1-104 for Pancreatic Cancer
The FDA has granted orphan drug designation to IMM-1-104 for pancreatic cancer.
FDA Grants Fast Track Designation to LP-184 for Glioblastoma
LP-184 has received fast track designation from the FDA for the treatment of patients with glioblastoma.
Lurbinectedin/Atezolizumab Combination Improves Survival in ES-SCLC
Lurbinectedin plus atezolizumab produced significant OS and PFS benefits as frontline maintenance for extensive-stage small cell lung cancer.
TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors
Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.
Hope With the Help of Dual I-O
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Increased ctDNA and MMR Testing May Alter Adjuvant and Neoadjuvant CRC Management
Benjamin Adam Weinberg, MD, discusses the prognostic value of adjuvant ctDNA testing in CRC and the role of immune checkpoint inhibition in dMMR CRC.
Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC
Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.
Novel Anti-Estrogen Therapies Are Poised to Expand Treatment Options in Advanced ER+ Breast Cancer
Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.
MAGIC-G1 Study Provides Updated Findings With MTX110 in Recurrent Glioblastoma
An update on PFS and OS data from the phase 1 MAGIC-G1 study of MTX110 in recurrent glioblastoma has been released.
FDA Approves Cologuard Plus for Adults at Average Risk for CRC
The FDA has approved Cologuard Plus, a next-generation multitarget stool DNA test, for adults at least 45 years of age who are at average risk…